Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

Figure 9

Effect of fenofibrate, metformin, and their combination on nitric oxide system. (a) The expression of endothelial nitric oxide synthase (eNOS) was analyzed by Western blot in the left ventricle of control- (CT-) and diabetic- (DB-) rats, subjected to sham (SH) or ischemia/reperfusion (I/R) injury, receiving 14 days of either vehicle, fenofibrate (F or Feno, 100 mg/kg), metformin (M or Metfor, 100 or 300 mg/kg), or Feno (50 mg/kg) + Metfor (50 mg/kg) and (b) tissue NO production and the activity of (c) eNOS and (d) iNOS. The bars represent the mean ± SEM of 4–6 different experiments. versus CTSH-Vehicle, versus DBSH-Vehicle, versus CTI/R-Vehicle, and versus DBI/R-Vehicle two-way ANOVA followed by Duncan’s post hoc test.

(a)

(b)

(c)

(d)